Article : Market is Large Enough for a Bare Minimum $1 Billion. AMRN VERY OVERSOLD. // LINK
Seeking Alpha (Saturday )
5 Stocks To Watch For Gains This Week
Mar 30 2013 By: Brian Nichols
The drug, as currently approved, has market potential around $1 billion, judging by the success of Lovaza. Due to the success of its trial ANCHOR and the market potential of elevated triglyceride levels, which is eight times larger, I am not sure how Amarin is not a buy right now for the long term, in addition to short term. Assuming its indication is expanded, as I believe it will, I think the market is large enough for a bare minimum $1 billion in sales. Therefore, with the stock being very oversold, I wouldn't be surprised to see pop off its current bottom range next week. In addition, if $1 billion in sales is achieved (minimum) then the typical 3-4 times sales should also be expected, therefore presenting great upside.